Continued progress in ongoing Phase 1/2 PYNNACLE study of PC14586, a first-in-class precision oncology investigational therapy in patients with advanced solid tumors with a p53 Y220C mutation; PMV expects to provide next clinical update in 2H 2023Enrolled first patient in combination arm of the PYNNACLE study with PC14586 and KEYTRUDA® (pembrolizumab)Cash, cash equivalents, and marketable securities of $243.5 million as of December 31, 2022 PRINCETON, N.J., March 01, 2023 (GLOBE NEWSWIRE) -- PMV
PRINCETON, N.J., Feb. 28, 2023 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (Nasdaq: PMVP; “PMV Pharma”), a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53, today announced that David H. Mack, Ph.D., President and Chief Executive Officer, will participate at the following investor conferences in March. Cowen’s 43rd Annual Health Care Conference (March 6-8, 2023)Format:Tumor Diagnostic Development Corporate PanelDate:W
The mean of analysts' price targets for PMV Pharmaceuticals, Inc. (PMVP) points to a 267.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.